Month: September 2020

CAMBRIDGE, Mass. – September 28, 2020 – Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, today announced the promotion of Abbas Kazimi to Chief Business Officer. Mr. Kazimi, who previously served as Vice President of Business Development, has more than 15 years of experience directing strategic transactions within the life sciences industry.

“Throughout his tenure with Nimbus, Abbas has played a central role in building our external partnerships, negotiating key transactions, and shaping our corporate strategy. We are exceptionally pleased to promote him to the role of Chief Business Officer,” said Jeb Keiper, M.S., MBA, Chief Executive Officer of Nimbus. “Abbas’ deep acumen in business and corporate development will be an asset for Nimbus as he moves into this expanded leadership role, and I look forward to continuing to partner with him to drive Nimbus’ success.”

Mr. Kazimi joined Nimbus in 2014 as Director of Business Development. In his roles at Nimbus, Mr. Kazimi drove several of the company’s transformative transactions, including the licensing agreement with Genentech in 2015, the sale of Nimbus’ clinical NASH program to Gilead up to an aggregate of $1.2 billion in 2016, and the strategic alliances with Celgene announced in 2017 and 2019. Prior to joining Nimbus, Mr. Kazimi spent a decade in planning and executing strategic transactions for life sciences clients with industry partners and financial investors across the globe. He earned his M.A. from Harvard University and his B.A. from the University of Texas at Austin.

About Nimbus Therapeutics

Nimbus Therapeutics designs breakthrough medicines. Utilizing its powerful structure-based drug discovery engine, Nimbus designs potent and selective small molecule compounds targeting proteins that are known to be fundamental drivers of pathology in highly prevalent human diseases and which have proven difficult for other drug makers to tackle. The company’s LLC/subsidiary architecture enables diverse and synergistic partnerships to deliver breakthrough medicines. Nimbus is headquartered in Cambridge, Mass. www.nimbustx.com.

Media Contact

Lisa Raffensperger, (617) 903-8783

Ten Bridge Communications

lisa@tenbridgecommunications.com

DOWNLOAD PRESS RELEASE

CAMBRIDGE, Mass. – September 1, 2020 – Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, today announced that it has appointed Scott Edmondson, Ph.D., as Senior Vice President, Head of Chemistry. Dr. Edmondson’s accomplished tenure in the biopharma industry, most recently as the Director and Head of Boston Oncology Chemistry at AstraZeneca, will be an asset in Nimbus’ work to advance therapeutic candidates for its recently expanded portfolio of promising targets across oncology, immunology and metabolism.

“We’re delighted to welcome Scott to Nimbus at such an exciting period of growth for the company,” said Peter Tummino, Ph.D., Chief Scientific Officer of Nimbus. “Scott’s extensive experience at building and leading world-class chemistry teams will be incredibly valuable as we progress our discovery efforts and lay the groundwork for our next generation of important small molecule therapeutics.”

Prior to joining Nimbus, Dr. Edmondson was the Director and Head of Boston Oncology Chemistry at AstraZeneca. In that role he oversaw recruiting, management and strategic direction for a team of over 30 chemists as well as management of an external international team of chemists. Previously, Dr. Edmondson was at Merck for 18 years in positions of ascending leadership, culminating in his role as Director of Discovery Chemistry. Over the course of his career at Merck, he led multiple cross-functional and cross-site teams as well as external collaborations. Dr. Edmondson has co-authored more than 50 publications and 55 patents. He holds a B.A. in chemistry from Cornell University, a Ph.D. in synthetic organic chemistry from The Ohio State University and completed a postdoc at Columbia University as an NIH Postdoctoral Fellow.

“I’m excited to join this exceptional team of drug hunters,” said Dr. Edmondson. “Nimbus’ unique position at the nexus of structural biology, computational chemistry and molecular sciences has driven the company’s long history of successes, and I’m eager to help lead the discovery efforts that will shape the company’s promising future pipeline.”

About Nimbus Therapeutics

Nimbus Therapeutics designs breakthrough medicines. Utilizing its powerful structure-based drug discovery engine, Nimbus designs potent and selective small molecule compounds targeting proteins that are known to be fundamental drivers of pathology in highly prevalent human diseases and which have proven difficult for other drug makers to tackle. The company’s LLC/subsidiary architecture enables diverse and synergistic partnerships to deliver breakthrough medicines. Nimbus is headquartered in Cambridge, Mass. www.nimbustx.com.

Media Contact

Lisa Raffensperger, (617) 903-8783
Ten Bridge Communications
lisa@tenbridgecommunications.com

DOWNLOAD PRESS RELEASE